A more recent paper analyzed 24 research studies on different treatment complications of thyroglossal cyst, and reported a total minor complications rate of 6% for the Sistrunk operation (classical or modified) and simple cystectomy treatment modalities. The Sistrunk procedure also showed better outcomes concerning the rate of overall recurrence, i.e. has the lowest rate of recurrence.Sistrunk procedure results in a 95% cure rate and 95–100% long-term survival. Epidemiology
90% of cases are presented in children before the age of 10 
70% of neck anomalies are from Thyroglossal cysts 
Thyroglossal Duct Cysts are the second most common neck abnormalities after lymphadenopathy
A person can live with a Thyroglossal Duct Cyst without any problems, until a pathology develops. Approximately 7% of the population has thyroglossal duct remnants 
Thyroglossal duct carcinoma occurs in approximately 1 to 2% of Thyroglossal cyst cases. See also
Cutaneous columnar cyst
Branchial cleft cyst
Cystic hygroma
Preauricular sinus and cyst
Ranula

References
Further reading
Brewis C, Mahadevan M, Bailey CM, Drake DP (2000). "Investigation and treatment of thyroglossal cysts in children". Journal of the Royal Society of Medicine. 93 (1): 18–21. doi:10.1177/014107680009300106. PMC 1288046. PMID 10700841.
http://www.doctoronline.nhs.uk/masterwebsite1Asp/targetpages/testandprocedures/surgery/thyroglo.asp


== External links ==
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer (NSCLC). It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer.The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.Sotorasib is an inhibitor of the RAS GTPase family.Sotorasib is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers. KRAS G12C mutations occur  in about 13% of patients with non-small cell lung cancers. Sotorasib was approved for medical use in the United States in May 2021, and in the European Union in January 2022. Medical uses
Sotorasib is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Clinical development
Sotorasib is being developed by Amgen. Phase I clinical trials were completed in 2020. In December 2019, it was approved to begin Phase II clinical trials.Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocarcinoma patients and 5% of colorectal cancer patients, and sotorasib is the first drug candidate to target this mutation, there have been high expectations for the drug.